PBYI Q4 2020 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M-16.5% YoY

Gross Profit

$42M79.2% margin

Operating Income

-$11M-21.2% margin

Net Income

-$15M-28.5% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$16M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$244M

Total Liabilities

$250M

Stockholders' Equity

-$6M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$63M	-16.5%
Gross Profit	$42M	$53M	-21.2%
Operating Income	-$11M	-$9M	-27.9%
Net Income	-$15M	-$11M	-33.9%

Revenue Segments

Product

$50M95%

Royalty

$3M5%